IL136209A0 - Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour - Google Patents

Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour

Info

Publication number
IL136209A0
IL136209A0 IL13620998A IL13620998A IL136209A0 IL 136209 A0 IL136209 A0 IL 136209A0 IL 13620998 A IL13620998 A IL 13620998A IL 13620998 A IL13620998 A IL 13620998A IL 136209 A0 IL136209 A0 IL 136209A0
Authority
IL
Israel
Prior art keywords
scour
diarrhea
phenyl
prevention
substituted
Prior art date
Application number
IL13620998A
Original Assignee
Childrens Medical Center
Harvard College
Ion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/159,333 external-priority patent/US6291449B1/en
Priority claimed from US09/159,337 external-priority patent/US20030134842A1/en
Application filed by Childrens Medical Center, Harvard College, Ion Pharmaceuticals Inc filed Critical Childrens Medical Center
Publication of IL136209A0 publication Critical patent/IL136209A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IL13620998A 1997-11-20 1998-11-20 Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour IL136209A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97559497A 1997-11-20 1997-11-20
US09/159,333 US6291449B1 (en) 1998-09-23 1998-09-23 Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
US09/159,337 US20030134842A1 (en) 1997-11-20 1998-09-23 Methods for the treatment or prevention of inflammatory diseases characterized by abnormal cell proliferation
PCT/US1998/024967 WO1999026628A1 (en) 1997-11-20 1998-11-20 Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour

Publications (1)

Publication Number Publication Date
IL136209A0 true IL136209A0 (en) 2001-05-20

Family

ID=27388303

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13620998A IL136209A0 (en) 1997-11-20 1998-11-20 Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour

Country Status (6)

Country Link
EP (1) EP1032394A1 (en)
JP (1) JP2001523720A (en)
AU (1) AU1598799A (en)
CA (1) CA2310773A1 (en)
IL (1) IL136209A0 (en)
WO (1) WO1999026628A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291449B1 (en) 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
AU2003212098B2 (en) * 2002-03-21 2008-07-24 Anadis Ltd Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
WO2003080082A1 (en) * 2002-03-21 2003-10-02 Anadis Ltd Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
US20240024335A1 (en) 2020-12-11 2024-01-25 Sanquin IP B.V. Treatment and prevention of anaemia of inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) * 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
EP0781128B1 (en) * 1994-09-16 2005-11-23 Children's Medical Center Corporation Clotrimazole metabolites in the treatment of sickle cell disease

Also Published As

Publication number Publication date
EP1032394A1 (en) 2000-09-06
WO1999026628A1 (en) 1999-06-03
JP2001523720A (en) 2001-11-27
AU1598799A (en) 1999-06-15
CA2310773A1 (en) 1999-06-03

Similar Documents

Publication Publication Date Title
EP0686203A4 (en) Compounds and methods for the diagnosis, treatment and prevention of diseases of cell death
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
AU4025599A (en) Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
AU2085201A (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
PL348059A1 (en) Compounds useful in the treatment of inflammatory diseases
AU2582897A (en) Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AU2639695A (en) Novel uses of triplex forming oligonucleotides for the treatment of human diseases
CY2538B1 (en) Tetrahydropyrido compounds
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
IL138814A0 (en) Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases
AU3967097A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
EP1126850A4 (en) Treatment of disorders of the outer retina
AU3187595A (en) Compounds for the treatment of restenosis
IL136209A0 (en) Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour
HK1038510A1 (en) Use of neurotrophic factor stimulators for the treamtent of ophthalmic neurodegenerative diseases.
MXPA01003761A (en) Remedies for ocular diseases.
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
IL136208A0 (en) Use of substituted diphenyl indanone, indane and indole compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scours
AU2754997A (en) The treatment of plant diseases
ZA962531B (en) Appliance for the discharge of crop protection agents
HK1010095A1 (en) Use of 8,9-dehydroestrone for the manufacture of amedicament for the treatment of diseases caused byfree radicals.
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases
ZA944671B (en) Medicaments for the treatment of inflammatory diseases